Udvalget for Veterinærlægemidler (CVMP) konkluderede, at fordelene ved Metacam var større end risiciene ved behandlingen, og anbefalede udstedelse af markedsføringstilladelse for Metacam.
The Committee for Medicinal Products for Veterinary Use (CVMP) decided that the benefits of Metacam are greater than any risks of treatment and they recommended that Metacam should be given a marketing authorisation.